Context-dependent induction of autoimmunity by TNF signaling deficiency

TNF inhibitors are widely used to treat inflammatory diseases; however, 30%–50% of treated patients develop new autoantibodies, and 0.5%–1% develop secondary autoimmune diseases, including lupus. TNF is required for formation of germinal centers (GCs), the site where high-affinity autoantibodies are...

Descripción completa

Detalles Bibliográficos
Autores principales: Quach, Tam D., Huang, Weiqing, Sahu, Ranjit, Diadhiou, Catherine M.M., Raparia, Chirag, Johnson, Roshawn, Leung, Tung Ming, Malkiel, Susan, Ricketts, Peta Gay, Gallucci, Stefania, Tükel, Çagla, Jacob, Chaim O., Lesser, Martin L., Zou, Yong-Rui, Davidson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983147/
https://www.ncbi.nlm.nih.gov/pubmed/35104241
http://dx.doi.org/10.1172/jci.insight.149094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983147/
https://www.ncbi.nlm.nih.gov/pubmed/35104241
http://dx.doi.org/10.1172/jci.insight.149094

Ejemplares similares